News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Guidance
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Director PRANN JOHN R JR sold 30,000 shares of CoreCivic Inc (CXW) on August 14, 2026, for approximately $966,300, reducing his direct ownership to 70,396 shares. This sale is part of a broader trend of insider selling at CoreCivic, with 16 insider sells and …
Thurgood Marshall Jr., a director at CoreCivic, sold 7,100 shares of common stock for $241,400 on August 13, 2026, reducing his direct holdings to 45,274 shares. This insider sale occurs as CoreCivic shares trade near their 52-week high, having gained 58% over the past …
CoreCivic's EVP and Chief Development Officer, Anthony L Grande, sold 801 shares of the company's common stock for $27,234 on August 13, 2026. This transaction follows a significant 58% surge in CoreCivic shares over the past year and comes after the company reported stronger-than-expected …
CoreCivic, Inc. director Harley G. Lappin reported two open-market sales of common stock in August 2026, totaling 25,032 shares. On August 14, 2026, he sold 3,000 shares at $32.69 each, and on August 13, 2026, he sold 22,032 shares at a weighted average price …
Nantahala Capital Management, alongside Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 2,807,830 shares, representing 9.99% of Unicycive Therapeutics, Inc. common stock as of June 30, 2026. This holding includes 1,406,383 shares acquirable through convertible securities within 60 days, with …
Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have reported a 9.99% beneficial ownership stake in Unicycive Therapeutics, Inc. (UNCY). This stake, detailed in an amended Schedule 13G filing, comprises 4,856,259 shares, which includes common stock and shares convertible from …
The Top 5 Analyst Questions From CoreCivic's Q2 Earnings Call CoreCivic's second quarter was marked by strong revenue growth and outperformance relative to Wall Street expectations, with management citing increased occupancy rates and higher demand from its federal government partners as primary drivers. CEO …
American Century Investment Management, along with its parent company American Century Companies Inc. and the Stowers Institute for Medical Research, has reported a 5.8% beneficial ownership in Civeo Corporation (CVEO), totaling 640,269 shares. Additionally, American Century ETF Trust holds 5.6% beneficial ownership (615,126 shares) …
Lucibeth Mayberry, Executive VP & Chief Strategy Officer at CoreCivic (NYSE:CXW), recently sold US$4.0m worth of stock at US$33.29 per share, reducing her holding by 61%. This transaction was the largest insider sale in the last year, raising some caution despite the sale occurring …
CoreCivic's EVP & CFO, David Garfinkle, recently sold CoreCivic stock totaling approximately $125,343, with transactions occurring on August 12 and 13, 2026. Following these sales and a charitable gift of 600 shares, Garfinkle directly holds 393,353 shares. The company's stock is trading near its …
CoreCivic, Inc. (CXW.US) officer, Patrick Swindle, sold 250,000 shares of common stock for a total of US$3.99 million. The transaction, executed on August 12, 2026, involved shares sold at an average price of US$15.96. Following this sale, Swindle now directly owns 184,874 shares of …
H.C. Wainwright has reiterated its Buy rating for Unicycive Therapeutics (UNCY.US) and maintained a price target of $15. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
An advocacy coalition, including justice, interfaith, and immigrant groups, has delivered a petition with 1,100 signatures to California Sen. Alex Padilla, urging him and Congress to push for in-person contact visitation at the California City ICE Detention Center. This initiative follows a vigil commemorating …
Unicycive Therapeutics (NASDAQ:UNCY) has received a consensus "Hold" rating from seven brokerages, with an average 12-month price target of $21.75, despite recent target reductions and downgrades from some firms. The company reported a quarterly loss of $0.06 per share, beating analyst estimates, and institutional …
Lucibeth Mayberry, EVP and Chief Innovation Officer at CoreCivic, Inc. (CXW), sold 120,000 shares of company stock for approximately $3.99 million on August 12, 2026. This sale occurred while the stock is trading near its 52-week high and is considered overvalued according to InvestingPro …
CoreCivic director Devin Murphy sold 8,098 shares of common stock at a weighted average price of $33.79 per share on August 12, 2026. The sale, classified as an open market or private transaction, ranged from $33.60 to $33.96 per share. Following this transaction, Murphy …
Unicycive Therapeutics reported its second-quarter 2026 financial results, with $61.4 million in cash, cash equivalents, and marketable securities, providing a runway into 2027. The company is focused on securing FDA approval for oxylanthanum carbonate (OLC) for hyperphosphatemia, with a facility inspection assigned for their …
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 11:00 a.m. ET CALL PARTICIPANTS Managing Director, Investor Relations - Jeb BachmannPresident and Chief Executive Officer - Patrick SwindleChief Financial Officer - David GarfinkleVice President of Finance - Brian Hammonds TAKEAWAYS Revenue -- …
This SEC filing is a Form 144 Notice of Proposed Sale of Securities for CoreCivic, Inc. (CXW). The filing details the proposed sale of 8,098 shares of common stock acquired through restricted stock lapse, with an aggregate market value of $273,610, and indicates the …
Analysts have cut the average 12-month price target for Unicycive Therapeutics, Inc. (UNCY) stock from $37.5 to $32.5, with individual forecasts ranging from $13 to $61 per share. Despite the cut, the new target still implies a significant 550% potential upside based on the …
Unicycive Therapeutics (NASDAQ:UNCY) reported a quarterly loss of $0.06 per share, significantly beating analyst expectations of a $0.47 loss. Following the positive earnings surprise, shares of UNCY traded up, and institutional investors have increased their holdings. Analyst sentiment remains mixed with a consensus "Hold" …
This article reports on the filing of a Form 8K by Unicycive Therapeutics Inc. on August 12. The brief announcement from Investing.com provides the date of the filing and the company name. The rest of the content includes market data, news headlines, and promotional …
Unicycive Therapeutics' shares rose after reporting a smaller-than-expected second-quarter loss of $0.06 per share, significantly beating the analyst consensus of $0.48 per share. The net loss narrowed to $1.7 million from $6.5 million due to a change in warrant liability fair value, despite increased …
Unicycive Therapeutics reported a net loss of $14.5 million for the first half of 2026, widening from $5.9 million in the prior year, primarily due to increased research and development and general and administrative expenses. Despite the larger loss, the company significantly boosted its …
Unicycive Therapeutics announced its Q2 2026 financial results, reporting $61.4 million in cash and securities, expected to fund operations into 2027. The company's lead drug, oxylanthanum carbonate (OLC), received a Complete Response Letter from the FDA due to third-party manufacturing deficiencies, but the FDA …
CoreCivic, a Tennessee-based private prison company, reported a revenue increase of over 27% to more than $680 million, largely driven by federal contracts with Immigration and Customs Enforcement (ICE). This growth aligns with increased migrant detention efforts by the Department of Homeland Security. The …
The article provides an earnings forecast for Civeo Corp (CVEO), highlighting a current earnings forecast score of 10.00, ranking 1st in the Real Estate Operations industry. Analysts have set an average price target of $28.00, with a "Strong Buy" rating from 2 analysts. The …
Search by ticker symbol or company name and select a result to open its chart.